[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-367248-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-367248-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","anticancer-efficacy-of-spiruchostatin-a-current-insights-into-histone-deacetylase-inhibition-and-oncologic-applications","Anticancer efficacy of Spiruchostatin A - current insights into histone deacetylase inhibition and oncologic applications","","Spiruchostatin A, also known as YM753 and OBP801, is a cyclic peptide natural product from Pseudomonas sp. It potently inhibits Class I histone deacetylases (HDACs), reshaping epigenetic regulation of genes involved in cell growth, apoptosis, and differentiation. This updated review evaluates antitumor activity across diverse cellular and animal models and examines mechanistic actions, biological effects, and potential clinical use, including synergy with other anticancer agents. Systematic searching covered PubMed/MedLine, Scopus, and Web of Science (Oct 2022–Feb 2023), emphasizing in vitro and in vivo evidence.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/anticancer-efficacy-of-spiruchostatin-a-current-insights-into-histone-deacetylase-inhibition-and-oncologic-applications/367248/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/anticancer-efficacy-of-spiruchostatin-a-current-insights-into-histone-deacetylase-inhibition-and-oncologic-applications/367248.png","ImageObject",300,407,{"name":42,"@type":43},"Riley","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-31","2026-09-23",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",6,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What is Spiruchostatin A and how does it work?","Question",{"text":63,"@type":64},"Spiruchostatin A (YM753/OBP801) is a cyclic peptide natural product that inhibits Class I histone deacetylases (HDACs). It promotes chromatin relaxation and transcriptional activation of tumor suppressor genes by increasing histone acetylation.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"What kinds of evidence does the review include?",{"text":68,"@type":64},"The review summarizes antitumor efficacy using studies that involve Spiruchostatin A in cancer treatment, covering both in vitro and in vivo cellular and animal models. The literature search used PubMed/MedLine, Scopus, and Web of Science from October 2022 to February 2023.",{"name":70,"@type":61,"acceptedAnswer":71},"What therapeutic advantages are highlighted for Spiruchostatin A?",{"text":72,"@type":64},"Spiruchostatin A shows significant antitumor activity, including inducing apoptosis and inhibiting tumor growth in multiple models. Its potential is especially noted when used synergistically with other anticancer agents to enhance efficacy.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},367248,1790816271,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,105,110,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":102,"show_sort_weight":103,"slug":104},"Technology",50,"technology",{"id":106,"doc_module":4,"doc_module_name":25,"category_name":107,"show_sort_weight":108,"slug":109},7,"Healthcare",40,"healthcare",{"id":111,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},8,30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":111,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":33,"preview_urls":146},1374391975076,"https://ap-avatar.wpscdn.com/avatar/14000253ca4ec9f6853?x-image-process=image/resize,m_fixed,w_180,h_180&k=1783305029341752051","Ibrahim et al. European Journal  \nEuropean Journal of Medical Research (2025) 30:169  \n[https://doi.org/10.1186/s40001-025-02401-0](https://doi.org/10.1186/s40001-025-02401-0 of Medical Research)[ of Medical Research](https://doi.org/10.1186/s40001-025-02401-0 of Medical Research)  \n REVIEW Open Access  \nAnticancer efficacy of Spiruchostatin A: current insights into histone deacetylase inhibition and oncologic applications  \nSaooda Ibrahim 1, Muhammad Umer Khan1*, Iqra Khurram 1, Muhammad Usman Ghani2, Javad Sharifi-Rad3,4,5* and Daniela Calina6*  \nAbstract  \nSpiruchostatin A also referred to as YM753 and OBP801, a cyclic peptide-based natural product derived from Pseudomonas sp., is distinguished by its potent inhibition of Class I histone deacetylases (HDACs) . The modulation of epigenetic mechanisms by HDAC inhibitors is fundamental for altering gene expression related to cell growth, apoptosis, and differentiation, highlighting their potential in oncologic therapies. This updated review assesses the antitumor efficacy of Spiruchostatin A across diverse cellular and animal models, scrutinizing its viability as a therapeutic agent against various cancers. A systematic literature review was executed by searching databases such as PubMed/ MedLine, Scopus, and Web of Science from October 2022 to February 2023. The inclusion criteria focused on studies involving Spiruchostatin A in the context of cancer treatment, including in vitro and in vivo models. The review concentrated on the compound’s mechanistic action, biological activity, and clinical applicability. Spiruchostatin A has demonstrated significant antitumor activities, including inducing apoptosis and inhibiting tumor growth effectively in multiple models. Its therapeutic potential is particularly noted in synergistic applications with other anticancer agents, enhancing its efficacy. Mechanistically, the compound facilitates chromatin relaxation and transcriptional activation of key tumor suppressor genes through increased histone acetylation. Spiruchostatin A exhibits substantial potential as an anticancer agent through effective HDAC inhibition and subsequent epigenetic modifications of cancer cell biology. However, comprehensive clinical trials are imperative to validate its efficacy and safety profiles comprehensively. Future research is warranted to elucidate detailed molecular mechanisms and to develop biomarkers for predicting treatment response. Comprehensive longitudinal clinical studies are also critical to establish Spiruchostatin A’s role within the broader oncological therapeutic regimen, along with the exploration of its analogs for improved therapeutic outcomes.  \nKeywords Anticancer, Epigenetics, HDAC inhibitor, Histone deacetylase, Spiruchostatin A, Therapeutic potential  \n*Correspondence:  \nMuhammad Umer Khan [muhammad.umer4@mlt.uol.edu.pk](muhammad.umer4@mlt.uol.edu.pk)[ ](muhammad.umer4@mlt.uol.edu.pk)Javad Sharifi-Rad [javad.sharifirad@gmail.com](javad.sharifirad@gmail.com)[ ](javad.sharifirad@gmail.com)Daniela Calina[calinadaniela@gmail.com](calinadaniela@gmail.com)  \nFull list of author information is available at the end of the article  \n© The Author(s) 2025. Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not per","cbCaieKkIS8WaZi2","https://ap.wps.com/l/cbCaieKkIS8WaZi2","pdf",1566455,15,"English","# Abstract\n# Introduction\n## Epigenetic mechanisms and cancer progression\n## Histone deacetylases and HDAC classes\n## Rationale for HDAC inhibitors in oncology","[{\"question\":\"What is Spiruchostatin A and how does it work?\",\"answer\":\"Spiruchostatin A (YM753/OBP801) is a cyclic peptide natural product that inhibits Class I histone deacetylases (HDACs). It promotes chromatin relaxation and transcriptional activation of tumor suppressor genes by increasing histone acetylation.\"},{\"question\":\"What kinds of evidence does the review include?\",\"answer\":\"The review summarizes antitumor efficacy using studies that involve Spiruchostatin A in cancer treatment, covering both in vitro and in vivo cellular and animal models. The literature search used PubMed/MedLine, Scopus, and Web of Science from October 2022 to February 2023.\"},{\"question\":\"What therapeutic advantages are highlighted for Spiruchostatin A?\",\"answer\":\"Spiruchostatin A shows significant antitumor activity, including inducing apoptosis and inhibiting tumor growth in multiple models. Its potential is especially noted when used synergistically with other anticancer agents to enhance efficacy.\"}]","Anticancer efficacy of Spiruchostatin A - current insights into histone deacetylase inhibition and oncologic applications | PDF",1790169884,38,[147,151,155,159],{"page_no":22,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/bd3879e98a8c2ee7c6b5e064e7d27c3f.webp",983,1305,{"page_no":26,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/54966519319d2139a5ce008425599ec2.webp",982,1304,{"page_no":30,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/6607ed9316b0f6135841345e345a06db.webp",981,1303,{"page_no":33,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/ae16ec09c913645238235a194d9975fa.webp",980,1301]